Price Alert

Corcept Therapeutics (CORT)

NASDAQ: CORT · Real-Time Price · USD

69.37

-1.97 (-2.76%)

At close: Sep 04, 2025, 3:59 PM

69.37

0.00%

Pre-market: Sep 05, 2025, 05:48 AM EDT

-2.76% (1D)

Bid	69.37
Market Cap	7.31B
Revenue (ttm)	716.08M
Net Income (ttm)	132.52M
EPS (ttm)	1.12
PE Ratio (ttm)	61.94
Forward PE	32.72
Analyst	Buy

Ask	73
Volume	540,120
Avg. Volume (20D)	1,057,803
Open	71.48
Previous Close	71.34
Day's Range	69.04 - 71.95
52-Week Range	33.66 - 117.33
Beta	0.20

About CORT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CORT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CORT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Corcept Therapeutics is scheduled to release its earnings on Oct 29, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-7.58%

Corcept Therapeutics shares are trading lower. The... Unlock content with Pro Subscription

4 months ago

-4.33%

Corcept Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, HC Wainwright maintained a Buy rating on the stock but lowered its price target from $150 to $145.

News

3 days ago · zacks.com

Can Korlym Drive Corcept's Growth Through the Rest of 2025?

CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.

1 week ago · zacks.com

Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?

CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.

4 weeks ago · seekingalpha.com

Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early

Corcept's Q2 2025 results were impacted by specialty pharmacy bottlenecks and discounting, masking robust underlying 60% growth in demand for its therapies. Revenue guidance was trimmed on fulfillment...

1 month ago · seekingalpha.com

Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript

Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2025 Earnings Call July 31, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Charles Robb - Chief Business Officer & Secret...

1 month ago · zacks.com

CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down

Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.

1 month ago · zacks.com

Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.32 per share a year ago.

1 month ago · businesswire.com

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog...

1 month ago · businesswire.com

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 31, 2025....